Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danavorexton for OSA patients undergoing abdominal surgery
NCT05814016Phase 2Terminated
- Sponsor
- Takeda
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of danavorexton in obstructive sleep apnea (OSA), sponsored by Takeda. Started May 2023; status: terminated.
02
Drugs
danavorexton
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05814016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814016.